{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:55:51Z","timestamp":1792068951716,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/bjc.2016.284","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T20:03:56Z","timestamp":1475006636000},"page":"1032-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder"],"prefix":"10.1038","volume":"115","author":[{"name":"on behalf of the EORTC Quality of Life Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S D","family":"Kaupp-Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Yadegarfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Finch-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C D","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S P","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Wiggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Al-Sarireh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"BFbjc2016284_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes CJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe B, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in International Clinical Trials in oncology. J Natl Cancer Inst 85: 365\u2013376.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2016284_CR2","first-page":"15564","volume":"26","author":"K Ahmed","year":"2008","unstructured":"Ahmed K, Beg MS, Komrokji R, Safa MM (2008) Intrahepatic versus extrahepatic cholangiocarcinoma: ss there a difference in survival? ASCO Meet Abstr 26: 15564.","journal-title":"ASCO Meet Abstr"},{"key":"BFbjc2016284_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","volume":"9","author":"CD Anderson","year":"2004","unstructured":"Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9: 43\u201357.","journal-title":"Oncologist"},{"key":"BFbjc2016284_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ijrobp.2006.05.061","volume":"66","author":"MA Ben-David","year":"2006","unstructured":"Ben-David MA, Griffith KA, Abu-Isa E, Lawrence TS, Knol J, Zalupski M, Ben-Josef E (2006) External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 66: 772\u2013779.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016284_CR5","unstructured":"Blazeby J, Sprangers M, Cull A, Groenvold M, Bottomley A (2011) EORTC Quality of Life Group Guidelines for Developing Questionnaire Modules (EORTC Quality of Life Group) 4th edition Brussels: EORTC Quality of Life study Group."},{"key":"BFbjc2016284_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/bjs.6471","volume":"96","author":"JM Blazeby","year":"2009","unstructured":"Blazeby JM, Fayers P, Conroy T, Sezer O, Ramage J, Rees M (2009) Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. Br J Surg 96: 291\u2013298.","journal-title":"Br J Surg"},{"key":"BFbjc2016284_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF02289113","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ, Warrington WG (1951) Time-limit tests: estimating their reliability and degree of speeding. Psychometrika 16: 167\u2013188.","journal-title":"Psychometrika"},{"key":"BFbjc2016284_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245: 755\u2013762.","journal-title":"Ann Surg"},{"key":"BFbjc2016284_CR9","unstructured":"Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A (2009) EORTC Quality of Life Group Translation Procedure, 3rd Edition EORTC Quality of life group: Brussels, Belgium."},{"key":"BFbjc2016284_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/0470846283","volume-title":"Quality of Life: Assessment, Analysis and Interpretation","author":"PM Fayers","year":"2000","unstructured":"Fayers PM (2000) Quality of Life: Assessment, Analysis and Interpretation. Wiley: New York, NY, USA."},{"key":"BFbjc2016284_CR11","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ- C30 Scoring Manual, 3rd edn EORTC Quality of life group: Brussels, Belgium."},{"key":"BFbjc2016284_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","volume":"35","author":"D Fitzsimmons","year":"1999","unstructured":"Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, B\u00fcchler MW, Dervenis C, Fernandez Cruz L, Friess H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35: 939\u2013941.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016284_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.bjc.6606086","volume":"104","author":"E Friend","year":"2011","unstructured":"Friend E, Yadegarfar G, Byrne C, Johnson CD, Sezer O, Pucciarelli S, Pereira SP, Chie W-C, Banfield A, Ramage JK (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104: 587\u2013592.","journal-title":"Br J Cancer"},{"key":"BFbjc2016284_CR14","unstructured":"Hays RD, Havashi T, Carson S, Ware JE (1988) User\u2019s Guide for the Multitrait Analysis Program (MAP) The RAND Corporation: Santa Monica, CA, USA."},{"key":"BFbjc2016284_CR15","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","volume":"20","author":"N Heffernan","year":"2002","unstructured":"Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L (2002) Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 20: 2229\u20132239.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016284_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00280-006-0380-9","volume":"60","author":"YS Hong","year":"2007","unstructured":"Hong YS, Lee J, Lee SC, Hwang IG, Choi S-H, Heo J-S, Park JO, Park YS, Lim HY, Kang WK (2007) Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60: 321\u2013328.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2016284_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1046\/j.1440-1746.2001.02520.x","volume":"16","author":"SP Kaushik","year":"2001","unstructured":"Kaushik SP (2001) Current perspectives in gallbladder carcinoma. J Gastroenterol Hepatol 16: 848\u2013854.","journal-title":"J Gastroenterol Hepatol"},{"key":"BFbjc2016284_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","volume":"366","author":"SA Khan","year":"2005","unstructured":"Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet (London, England) 366: 1303\u20131314.","journal-title":"Lancet (London, England)"},{"key":"BFbjc2016284_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jhep.2006.09.001","volume":"45","author":"H Malhi","year":"2006","unstructured":"Malhi H, Gores GJ (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856\u2013867.","journal-title":"J Hepatol"},{"key":"BFbjc2016284_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1055-9965.EPI-05-0811","volume":"15","author":"KA McGlynn","year":"2006","unstructured":"McGlynn KA., Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15: 1198\u20131203.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFbjc2016284_CR21","first-page":"285","volume":"19","author":"F Mihalache","year":"2010","unstructured":"Mihalache F, Tantau M, Diaconu B, Acalovschi M (2010) Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis 19: 285\u2013290.","journal-title":"J Gastrointestin Liver Dis"},{"key":"BFbjc2016284_CR22","unstructured":"Nunnally J, Bernstein IH (1994) Psychometric Theory, 3rd edn McGrawHill: New York, NY, USA."},{"key":"BFbjc2016284_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MOG.0b013e3280495451","volume":"23","author":"T Patel","year":"2007","unstructured":"Patel T, Singh P (2007) Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 23: 317\u2013323.","journal-title":"Curr Opin Gastroenterol"},{"key":"BFbjc2016284_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115\u2013125.","journal-title":"Semin Liver Dis"},{"key":"BFbjc2016284_CR25","volume-title":"Using Multivariate Statistics","author":"BJFL Tabachnik","year":"1993","unstructured":"Tabachnik BJ FL (1993) Using Multivariate Statistics. Harper and Row: London, UK."},{"key":"BFbjc2016284_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273\u20131281.","journal-title":"N Engl J Med"},{"key":"BFbjc2016284_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 The UK ABC-01 Study. Br J Cancer 101: 621\u2013627.","journal-title":"Br J Cancer"},{"key":"BFbjc2016284_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E","volume":"17","author":"SD Walter","year":"1998","unstructured":"Walter SD, Eliasziw M, Donner A (1998) Sample size and optimal designs for reliability studies. Stat Med 17: 101\u2013110.","journal-title":"Stat Med"},{"key":"BFbjc2016284_CR29","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1097\/NCC.0000000000000233","volume":"38","author":"S Woradet","year":"2015","unstructured":"Woradet S, Promthet S, Songserm N, Parkin DM (2015) Factors affecting health-related quality of life in patients with cholangiocarcinoma in the northeastern region of Thailand. Cancer Nurs 38: E46\u2013E51.","journal-title":"Cancer Nurs"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:33:55Z","timestamp":1684416835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFbjc2016284"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.284","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]},"assertion":[{"value":"17 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}